|
Click here to download the press release as a PDF-file ProQinase will identify novel biomarkers for anti-tumour therapies as member of the EU-research consortium „ANGIOTARGETING - European Consortium for Tumour Angiogenesis Research” Freiburg, February 2007 FREIBURG. Reliable prediction about success or failure of new anti-tumour therapies can be provided by so-called biomarkers. Biomarkers are patient characteristics, e.g. presence of specific proteins, of which the amount changes as result of a therapeutic intervention. Detection of biomarkers in peripheral blood of tumour patients can represent a simple and uninvasive method to determine success or failure of a given treatment.
As part of an EU-funded research programme ProQinase, a business division of KTB Tumorforschungsgesellschaft mbH at the Tumorbiology Center Freiburg, will identify novel potential biomarkers. In January 2007 ProQinase became a partner of the „European Consortium for Tumour Angiogenesis Research“, an integrated project that is funded by the EU with 6 Mio Euro. Aim of the research programme is the investigation of mechanisms that control the formation of novel blood vessels in tumours (tumour angiogenesis) and the development of novel therapeutical approaches. Fourteen laboratories from ten countries are participating in the project that is coordinated by the University of Bergen, Norway (http://www.uib.no/med/angiotargeting/). ProQinase uses its Integrated Technology platform to develop kinase inhibitors and to identify, to develop and to carry-out biomarker assays (www.proqinase.com). The company is today one of the biggest service providers of preclinical technologies in the field of protein kinases. As part of the EU-research project these resources will be used under the supervision of Dr. Michael Kubbutat (Head Research & Development, ProQinase) for the identification of novel potential biomarkers. „Identification and development of biomarker is pivotal for the verification and application of novel therapies in oncology. Biomarkers will allow verification of the mechanism of action and the efficacy of drugs and can help to select the best therapy for the individual patient“, states Kubbutat. „ProQinase offers already several Biomarker-assays for clinical studies, however, for most novel therapies suitable biomarker are heavily missed. With the help of the EU-funding ProQinase can increase significantly its effort to identify novel biomarkers in cooperation with research groups from academia and industry“. Contact
Dr. Michael Kubbutat
ProQinase/
KTB Tumorforschungsgesellschaft mbH
Tumor Biology Center Freiburg
Breisacher Str. 117
79106 Freiburg
Germany
m.kubbutat@proqinase.com
www.proqinase.com Barbara Riess
Tumor Biology Center Freiburg
Kommunikation und Öffentlichkeitsarbeit
Breisacher Str. 117
Visitor’s address: Lehener Str. 86
79106 Freiburg
Germany Tel. +49 761 206-1109
Fax +49 761 206-1107
riess@tumorbio.uni-freiburg.de Click here to download the press release as a PDF-file
|
